| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Dec'18 | ||
|---|---|---|---|---|---|---|
Assets | ||||||
Current assets: | ||||||
Cash and cash equivalents | ||||||
757,049 | 363,773 | 413,973 | 112,400 | 436,086 | ||
Short-term marketable securities | ||||||
148,126 | 182,220 | 122,080 | - | - | ||
Prepaid expenses and other current assets | ||||||
19,782 | 22,629 | 22,102 | - | 9,137 | ||
Total current assets | ||||||
924,957 | 568,622 | 558,155 | - | 445,223 | ||
Property and equipment, net | ||||||
15,755 | 5,625 | 2,984 | - | 1,575 | ||
Operating lease right-of-use assets, net | ||||||
8,855 | - | - | - | - | ||
Long-term marketable securities | ||||||
23,210 | 31,144 | 75,886 | - | - | ||
Investments in nonconsolidated entities | ||||||
- | - | 907 | - | 17,050 | ||
Other assets | ||||||
17,022 | 26,288 | 2,598 | - | 1,093 | ||
Total assets | ||||||
989,799 | 631,679 | 640,530 | - | 464,941 | ||
Current liabilities: | ||||||
Accounts payable | ||||||
13,086 | 8,852 | 10,270 | - | 13,509 | ||
Accrued compensation and benefits | ||||||
5,647 | 13,317 | 7,580 | - | 4,047 | ||
Accrued research and development liabilities | ||||||
29,522 | 20,896 | 13,198 | - | 8,915 | ||
Accrued professional services | ||||||
3,145 | 2,222 | - | - | 772 | ||
Accrued distributions to stockholders | ||||||
- | - | - | - | 997 | ||
LEO call option liability | ||||||
3,539 | 4,078 | 4,021 | - | 3,009 | ||
Build-to-suit lease obligation | ||||||
- | 8,000 | - | - | - | ||
Operating lease liabilities, current portion | ||||||
2,510 | - | - | - | - | ||
Other accrued liabilities | ||||||
7,465 | 3,020 | 4,789 | - | 1,328 | ||
Total current liabilities | ||||||
64,914 | 60,385 | 39,858 | - | 32,577 | ||
Term loans, noncurrent | ||||||
92,416 | 91,791 | 75,017 | - | 54,507 | ||
2027 Notes | ||||||
368,923 | - | - | - | - | ||
Operating lease liabilities, net of current portion | ||||||
8,678 | - | - | - | - | ||
Other liabilities | ||||||
2,797 | 3,527 | 1,388 | - | 495 | ||
Total liabilities | ||||||
537,728 | 155,703 | 116,263 | - | 87,579 | ||
Redeemable convertible noncontrolling interests | ||||||
3,053 | 2,243 | 2,570 | - | 122 | ||
Stockholders’ equity: | ||||||
Common stock, $0.001 par value; 500,000,000 shares authorized; 123,774,536 shares issued and 121,359,855 shares outstanding as of March 31, 2020, 123,658,287 shares issued and outstanding as of December 31, 2019 | ||||||
124 | 124 | 117 | - | 92 | ||
Treasury stock, at cost; 2,414,681 shares as of March 31, 2020 | ||||||
75,000 | - | - | - | - | ||
Additional paid-in capital | ||||||
986,746 | 848,107 | 826,062 | - | 494,231 | ||
Accumulated other comprehensive income | ||||||
726 | 254 | 152 | - | - | ||
Accumulated deficit | ||||||
-531,881 | -440,031 | -366,573 | -69 | -179,444 | ||
Total BridgeBio stockholders' equity | ||||||
380,715 | 408,454 | 459,758 | - | 314,879 | ||
Noncontrolling interests | ||||||
68,303 | 65,279 | 61,939 | - | 62,361 | ||
Total stockholders' equity | ||||||
449,018 | 473,733 | 521,697 | - | 377,240 | ||
Total liabilities, redeemable convertible noncontrolling interests and stockholders’ equity | ||||||
989,799 | 631,679 | 640,530 | - | 464,941 | ||
BridgeBio Pharma LLC | ||||||
Cash and cash equivalents | ||||||
- | - | - | 293,803 | - | ||
Prepaid expenses and other current assets | ||||||
- | - | - | 12,906 | - | ||
Total current assets | ||||||
- | - | - | 306,709 | - | ||
Property and equipment, net | ||||||
- | - | - | 1,865 | - | ||
PellePharm investment | ||||||
- | - | - | 7,495 | - | ||
Other assets | ||||||
- | - | - | 9,471 | - | ||
Total assets | ||||||
- | - | - | 325,540 | - | ||
Accounts payable | ||||||
- | - | - | 16,065 | - | ||
Accrued compensation and benefits | ||||||
- | - | - | 4,736 | - | ||
Accrued research and development liabilities | ||||||
- | - | - | 9,419 | - | ||
LEO call option liability | ||||||
- | - | - | 4,297 | - | ||
Other accrued liabilities | ||||||
- | - | - | 4,188 | - | ||
Total current liabilities | ||||||
- | - | - | 38,705 | - | ||
Term loans, noncurrent | ||||||
- | - | - | 74,997 | - | ||
Other liabilities | ||||||
- | - | - | 347 | - | ||
Total liabilities | ||||||
- | - | - | 114,049 | - | ||
Accumulated deficit | ||||||
- | - | - | -326,068 | - | ||
Total BridgeBio members’ deficit | ||||||
- | - | - | -326,068 | - | ||
Noncontrolling interests | ||||||
- | - | - | 48,391 | - | ||
Total members’ deficit | ||||||
- | - | - | -277,677 | - | ||
Total liabilities and stockholders’ deficit | ||||||
- | - | - | 325,540 | - | ||